CITADEL ADVISORS LLC - 30 Sep 2025 SCHEDULE 13G/A Report for BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares") (BBOT)

Filing Manager
CITADEL ADVISORS LLC
Reporting Manager
Kenneth Griffin
Security
BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares")
Symbol
BBOT
Shares outstanding
79,316,938 shares
Disclosed Ownership
2,538,142 shares
Ownership
3.2%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:09:22 UTC
Date of event
30 Sep 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Citadel Advisors LLC 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Advisors Holdings LP 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel GP LLC 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities LLC 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities Group LP 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities GP LLC 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Kenneth Griffin 3.2% 2,538,142 0 2,538,142 /s/ Seth Levy Seth Levy, attorney-in-fact*